Last update 21 Aug 2026
Beijing Shuoxing Biomedical Technology Co. Ltd.

Beijing Shuoxing Biomedical Technology Co. Ltd.

Holding Company|2019|Guangdong Sheng, China|
www.starmab.com.cn

Overview

Tags

Neoplasms
Hemic and Lymphatic Diseases
Skin and Musculoskeletal Diseases
Antibody
Nanobody
Bispecific antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms7
Hemic and Lymphatic Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Antibody4
Nanobody3
Bispecific antibody3
Tetraspecific antibody1
Top 5 TargetCount
CD40 x CD47 x SIRPα1
CD16a x EGFR1
CD16a(Low affinity immunoglobulin gamma Fc region receptor III-A)1
CD28 x EGFR x PDL1 x albumin1
4-1BB x CD401

Related

10
Drugs associated with Beijing Shuoxing Biomedical Technology Co. Ltd.
SM-2275
Target
CD28 x EGFR x PDL1 x albumin
Mechanism
CD28 agonists [+3]
Active Org.
Beijing Shuoxing Biomedical Technology Co. Ltd.Beijing Shuoxing Biomedical Technology Co. Ltd.
Originator Org.
Beijing Shuoxing Biomedical Technology Co. Ltd.Beijing Shuoxing Biomedical Technology Co. Ltd.
Active Indication
Metastatic Solid Tumor [+2]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
SM3321
Target
CD16a
Mechanism
CD16a agonists
Active Org.
Beijing Shuoxing Biomedical Technology Co. Ltd.Beijing Shuoxing Biomedical Technology Co. Ltd.
Originator Org.
Beijing Shuoxing Biomedical Technology Co. Ltd.Beijing Shuoxing Biomedical Technology Co. Ltd.
Active Indication
Locally Advanced Malignant Solid Neoplasm [+4]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
SM-2279
Target-
Mechanism-
Active Org.
Beijing Shuoxing Biomedical Technology Co. Ltd.Beijing Shuoxing Biomedical Technology Co. Ltd.
Originator Org.
Beijing Shuoxing Biomedical Technology Co. Ltd.Beijing Shuoxing Biomedical Technology Co. Ltd.
Active Indication
Solid tumor
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Beijing Shuoxing Biomedical Technology Co. Ltd.
NCT07750132
/ Not yet recruitingPhase 1
A First-in-Human, Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Activity of SM2275 in Patients With Advanced Solid Tumors
NCT06087770
/ CompletedPhase 1
An Open-label, Dose-escalation Phase Ia Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of SM3321 in Patients With Locally Advanced or Metastatic Solid Tumors
100 Clinical Results associated with Beijing Shuoxing Biomedical Technology Co. Ltd.
Login to view more data
0 Patents (Medical) associated with Beijing Shuoxing Biomedical Technology Co. Ltd.
Login to view more data
100 Deals associated with Beijing Shuoxing Biomedical Technology Co. Ltd.
Login to view more data
100 Translational Medicine associated with Beijing Shuoxing Biomedical Technology Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Aug 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
3
5
Preclinical
Phase 1
2
14
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
SM-2275
 ( CD28 x EGFR x PDL1 x albumin )		Advanced Malignant Solid Neoplasm
More
Phase 1
SM3321
 ( CD16a )		Hematologic Neoplasms
More
IND Application
SM-2280
Solid tumor
More
Preclinical
SM2256
 ( 4-1BB x CD40 )		Solid tumor
More
Preclinical
SM-2279
Solid tumor
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free